Trials / Completed
CompletedNCT03961880
Impact of Recurrence Score on Adjuvant Treatment Decisions in Breast Cancer Patients
Impact of Recurrence Score on Adjuvant Treatment Decisions and Tumor Cell Dissemination in Estrogen-receptor Positive and HER2 Negative Patients With Early Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 270 (actual)
- Sponsor
- University Hospital Tuebingen · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
IRMA is a Prospective, monocenter, non-interventional investigator initiated (IIT) registry that aims to investigate the use of the CE-marked OncotypeDX and its impact on adjuvant therapy recommendations in the clinical routine. Additionally, the proportion of patients with low, intermediate and high RS in predefined clinical subgroups will be determined. To evaluate the impact of the RS on tumor cell dissemination, these subgroups also include DTC-negative versus DTC-positive patients.
Conditions
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2025-06-30
- Completion
- 2025-06-30
- First posted
- 2019-05-23
- Last updated
- 2025-09-16
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03961880. Inclusion in this directory is not an endorsement.